Mario Balsa/X
Jul 30, 2025, 13:12
Mario Balsa: ASCO 2025 Guideline Updates on Stage IV NSCLC with Driver Alterations
Mario Balsa, Medical Oncology resident at Institut Català d’Oncologia (ICO), shared on X about a recent paper by Joshua E. Reuss et al. published in JCO:
“ASCO 2025 guideline updates on stage IV NSCLC with driver alterations
- EGFR: Osimertinib remains top
- ALK: Alectinib or Lorlatinib. ¿Brigatinib? Twirl and exit
- KRAS G12C: Sotorasib/Adagrasib post-CT
A living document for a fast-evolving field. Lung cancer doesn’t stand still, and neither should we.”
Title: Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1
Authors: Joshua E. Reuss, Sara Kuruvilla, Nofisat Ismaila, Ibrahim Hanna Azar, Jill Feldman, Naoki Furuya, Paul Wheatley-Price, Logan Roof, Ana I. Velazquez, Yubao Wang, Natasha B. Leighl.
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 30, 2025, 12:52
Jul 30, 2025, 11:57
Jul 30, 2025, 10:36
Jul 30, 2025, 10:32
Jul 30, 2025, 10:15
Jul 30, 2025, 10:04